CLEC12A and acute myeloid leukemia: CLL-1 is a commonly studied marker of AML due to its relatively high expression on both leukemic stem cells (approximately 45%) and leukemic blasts (between 77.5% to 92%) with a high proportion of AML patients (> 85%) expressing CLL-1.